Friday, January 02, 2026 12:17:26 PM
So you migrated as well...r
Recent HALO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:10:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 08:09:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:06:06 PM
- HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 05/11/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:04:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:04:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:03:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:02:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:01:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:16:24 PM
- Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets • PR Newswire (US) • 05/07/2026 01:00:00 PM
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology • PR Newswire (US) • 05/06/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 09:05:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:45:44 PM
- Halozyme to Report First Quarter 2026 Financial and Operating Results • PR Newswire (US) • 04/30/2026 08:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 02:39:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:12:51 PM
- Halozyme Appoints Darren Snellgrove as Chief Financial Officer • PR Newswire (US) • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:06:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 09:13:42 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:28:38 PM
